Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
World Neurosurgery 2020-May

Flow Diversion Endovascular Treatment Improves Headaches in Patients with Unruptured Intracranial Aneurysms.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
L'enllaç es desa al porta-retalls
Georgios Maragkos
Sarah Cordell
Santiago Gomez-Paz
Laura Dodge
Mohamed Salem
Luis Ascanio
Diane DiNobile
Abdulrahman Alturki
Justin Moore
Christopher Ogilvy

Paraules clau

Resum

Headaches are the presenting symptom of unruptured intracranial aneurysms (UIA) in over one-third of cases. Several patients may expect their headaches to remit after aneurysm treatment. This study aims to identify factors influencing headache outcomes following endovascular treatment of UIAs.A prospective, observational study was conducted on patients with UIAs treated with flow diversion. Subjects reported their headache intensity with the Visual Analogue Scale (VAS) and were given three surveys prior to treatment: Migraine Disability Assessment (MIDAS), Headache Impact Test (HIT-6), and Patient Health Questionnaire-2 (PHQ-2). Follow-up was at one, three and six months after treatment. Analysis was performed using generalized mixed effects models (GLMM).We identified 38 patients, 29 of whom reported headaches at baseline (76.3%). Mean (SD) age was 55.3±12.4 years, and 79% of patients were female. Mean (SD) aneurysmal diameter was 6.8±5.3 mm, and treatment modality was Pipeline embolization in all cases. At last follow-up, 5 (15.1%) aneurysms were incompletely occluded. Mean (SD) VAS scores for patients with headaches at baseline were 4.36±0.59 at baseline, 4.08±0.60 at one-month, 3.04±0.62 at three-month, and 2.76±0.57 at six-month follow-up. Controlling for occlusion status, medication, and depression, there was significant improvement at three- and six month-follow-up. Similar patterns were observed with MIDAS and HIT-6.In the present study, endovascular UIA treatment lead to significantly decreased headache intensity for patients with headaches at baseline, after a short time delay. Our data can shed light on post-intervention headache patterns and help inform patient discussions and treatment expectations.

Uneix-te a la nostra
pàgina de Facebook

La base de dades d’herbes medicinals més completa avalada per la ciència

  • Funciona en 55 idiomes
  • Cures a base d'herbes recolzades per la ciència
  • Reconeixement d’herbes per imatge
  • Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
  • Llegiu publicacions científiques relacionades amb la vostra cerca
  • Cerqueu herbes medicinals pels seus efectes
  • Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents

Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades

Google Play badgeApp Store badge